TXMD


Oppenheimer Sees 125% Upside for TherapeuticsMD (TXMD) Stock; Here’s Why

Oppenheimer analyst Jay Olson is out today with a bullish research note on shares of TherapeuticsMD (NASDAQ:TXMD), after the drug maker reported second-quarter results and …

Cantor Pounds the Table on TherapeuticsMD (TXMD) Stock

Cantor analyst William Tanner is out pounding the table on shares of TherapeuticsMD (NASDAQ:TXMD), reiterating an Overweight rating and price target of $26, which implies an …

Are These Two Healthcare Stocks Great Bargains? Analysts Say Yes

By Harriet Lefton You don’t need to spend big to pick up premium stock picks… not when you can use the markets’ current …

TherapeuticsMD (TXMD): With Access to Capital in Place, Eyes Will Likely Turn to Imvexxy Launch, Says Cantor

Cantor analyst William Tanner is out today with a research note on shares of TherapeuticsMD (NYSE:TXMD), after the women’s healthcare company announced that …

TherapeuticsMD (TXMD) Stock Climbs, Oppenheimer Sees 80% Upside

Oppenheimer analyst Jay Olson today offers up some tidbits about the upcoming launch of TherapeuticsMD’s (NYSE :TXMD) lead drug Imvexxy. Olson rates TXMD …

Oppenheimer Boosts Price Target on TherapeuticsMD (TXMD) as It Introduces Imvexxy

TherapeuticsMD (NASDAQ:TXMD) announced this morning that the FDA approved TX-004 for treating symptoms of vulvar and vaginal atrophy (VVA). Once designated as Yuvexxy, …

TherapeuticsMD (TXMD): A Textbook Case of Buy the Rumor, Sell the News?

It’s hard to make money when FDA approvals are priced in, but Cantor analyst remains bullish.

Cantor Sees 280% Upside for TherapeuticsMD (TXMD) Stock; Here’s Why

Now that TXMD has disproved the bears with a key victory for Imvexxy, Cantor’s William Tanner angles for another win come October for TX-001.

Watch Out for These Pharmaceutical Players Racing Toward FDA Approvals

Will the FDA writing on the wall bode well for three pharmaceutical firms raring for a PDUFA nod this summer? Achaogen (NASDAQ:AKAO) complicated …

TherapeuticsMD’s (TXMD) TX-004 Takes a Step Forward to FDA Approval, Says Cantor

TherapeuticsMD (NASDAQ:TXMD) investors have a smile on their faces Wednesday, after the drug maker disclosed that it has entered into negotiations with the FDA regarding …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts